Spruce Biosciences, Inc.

As of May 15, 2023, Spruce Biosciences, Inc. is considered risky and overvalued due to its low Price to Book Value of 0.18, an EV to EBITDA ratio of 0.37, and significant underperformance with a stock return of -73.54% over the past year, despite a high ROCE of 670.25% and a concerning negative ROE of -361.86%.

As of May 15, 2023, Spruce Biosciences, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 0.18, an EV to EBITDA ratio of 0.37, a negative Return on Equity of -361.86%, and a year-to-date stock performance decline of 83.33%.

As of June 17, 2025, the trend is mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals, and overall monthly indicators remain bearish, reflecting a negative performance year-to-date and over the past year.

As of March 2022, the management team of Spruce Biosciences, Inc. includes Mr. Michael Grey (Chairman of the Board), Mr. Richard King (CEO and Director), and Dr. Niall O'Donnell (Director).

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing therapies for endocrine disorders, particularly congenital adrenal hyperplasia (CAH). It has a market cap of $3.07 million and reported a net profit loss of $14 million as of March 2025.

As of Jun 18, Spruce Biosciences, Inc. has a market capitalization of 3.07 million, with net sales of 2.91 million and a net profit of -55.45 million over the last four quarters. The company reported shareholder's funds of 28.82 million and total assets of 45.21 million as of Dec 24.